HomeCompareHSNGF vs ABBV

HSNGF vs ABBV: Dividend Comparison 2026

HSNGF yields 3.16% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HSNGF wins by $536.82M in total portfolio value· pulled ahead in Year 3
10 years
HSNGF
HSNGF
● Live price
3.16%
Share price
$15.81
Annual div
$0.50
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$536.93M
Annual income
$506,158,955.34
Full HSNGF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HSNGF vs ABBV

📍 HSNGF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHSNGFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HSNGF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HSNGF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HSNGF
Annual income on $10K today (after 15% tax)
$268.62/yr
After 10yr DRIP, annual income (after tax)
$430,235,112.04/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HSNGF beats the other by $430,214,056.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HSNGF + ABBV for your $10,000?

HSNGF: 50%ABBV: 50%
100% ABBV50/50100% HSNGF
Portfolio after 10yr
$268.51M
Annual income
$253,091,863.55/yr
Blended yield
94.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HSNGF
No analyst data
Altman Z
0.3
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HSNGF buys
0
ABBV buys
0
No recent congressional trades found for HSNGF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHSNGFABBV
Forward yield3.16%3.06%
Annual dividend / share$0.50$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$536.93M$102.3K
Annual income after 10y$506,158,955.34$24,771.77
Total dividends collected$534.66M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: HSNGF vs ABBV ($10,000, DRIP)

YearHSNGF PortfolioHSNGF Income/yrABBV PortfolioABBV Income/yrGap
1$11,332$632.06$11,550$430.00$218.00ABBV
2$13,464$1,338.78$13,472$627.96$8.00ABBV
3← crossover$17,380$2,973.20$15,906$926.08+$1.5KHSNGF
4$25,770$7,173.61$19,071$1,382.55+$6.7KHSNGF
5$47,456$19,881.73$23,302$2,095.81+$24.2KHSNGF
6$119,212$68,434.30$29,150$3,237.93+$90.1KHSNGF
7$448,887$321,330.41$37,536$5,121.41+$411.4KHSNGF
8$2,741,910$2,261,600.57$50,079$8,338.38+$2.69MHSNGF
9$28,755,150$25,821,306.66$69,753$14,065.80+$28.69MHSNGF
10$536,926,966$506,158,955.34$102,337$24,771.77+$536.82MHSNGF

HSNGF vs ABBV: Complete Analysis 2026

HSNGFStock

Hang Seng Bank Limited, together with its subsidiaries, provides various banking and related financial services to individual, corporate, commercial, small and medium-sized enterprise, and institutional customers in Hong Kong, Mainland China, and internationally. It operates through four segments: Wealth and Personal Banking, Commercial Banking, Global Banking and Markets, and Other. The company offers personal banking services, including current and savings accounts, time deposits, mortgages and personal loans, credit cards, and insurance, investment, and other wealth management services, as well as consumer lending services. It also provides corporate lending, trade and receivable finance, payments and cash management, treasury and foreign exchange, general insurance, key-person insurance, investment services, and corporate wealth management; and general banking, corporate lending, interest rates, foreign exchange, money markets, structured products and derivatives, etc. In addition, the company offers retirement benefits, life assurance, fund management, and stock broking services, as well as index compilation and licensing; fund raising and sales; and asset management services. It operates approximately 280 service outlets in Hong Kong; branches in Macau and Singapore; and a representative office in Taipei, Taiwan. Hang Seng Bank Limited, through its subsidiary, Hang Seng Bank (China) Limited, also operates a network of outlets in approximately 20 cities in Mainland China. The company was founded in 1933 and is headquartered in Central, Hong Kong. Hang Seng Bank Limited is a subsidiary of The Hongkong and Shanghai Banking Corporation Limited.

Full HSNGF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HSNGF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HSNGF vs SCHDHSNGF vs JEPIHSNGF vs OHSNGF vs KOHSNGF vs MAINHSNGF vs JNJHSNGF vs MRKHSNGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.